Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Patient-derived tumor organoids with p53 mutations, and n... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
0
Authors
Florencia Rowdo
27 more
Florencia Rowdo
•
Olufunmilayo Olopade
25 more
•
Jill Bargonetti
Published
June 22, 2023
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Genetics
Cancer
Molecular Biology
Show all topics
DOI
10.1101/2023.06.22.544406
License
CC-BY-NC-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Genetics
Cancer
Molecular Biology
Show all topics
DOI
10.1101/2023.06.22.544406
License
CC-BY-NC-ND
Other Formats
PDF
